Parallel Industries Inc.

Equities

EAPH

US2777741057

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 09:52:05 2024-04-24 am EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	0.00%

2021	Parallel Industries Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2021	CI
2019	Easton Pharmaceuticals Inc. cancelled the acquisition of Boutique Hotel and Real Estate Asset in the Heart of Toronto, Ontario, Canada.	CI

Easton Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019

June 13, 2019 at 08:30 am EDT

Easton Pharmaceuticals Inc. reported earnings results for the first quarter ended March 31, 2019. In the first quarter of 2019, the company recorded revenues of $612,689 and turned from a loss to post net income of $7,878.

Latest news about Parallel Industries Inc.

Parallel Industries Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2021	21-12-22	CI
Easton Pharmaceuticals Inc. cancelled the acquisition of Boutique Hotel and Real Estate Asset in the Heart of Toronto, Ontario, Canada.	19-09-26	CI
Easton Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-06-13	CI
Easton Pharmaceuticals Inc. Moves its Corporate Head Office	19-04-30	CI
Easton Pharmaceuticals Inc. acquired Supreme Sweets Inc. from Barbara and Mario Parravano.	19-04-25	CI
Easton Pharmaceuticals Inc. Signs LOI with Licensed Producer of Cannabis to Expand its Operations and Participate in its Cannabis Edibles Division	19-03-27	CI
Easton Pharmaceuticals Inc. Commences Cannabis Edibles Division	19-03-10	CI
Easton Pharmaceuticals Inc. Announces Updates on its $2,600,000 Framing Contract to Construct 150 Homes as Well as Other Initiatives	19-02-05	CI
Easton Pharmaceuticals Inc. Announces Sales Results for the Quarter Ended September 30, 2018 and December 31, 2018	19-01-23	CI
Easton Pharmaceuticals Inc. Provides Operational Update on CAD 2,600,000 Framing Contract	19-01-11	CI
Easton Pharmaceuticals Announces Signing and Commencement of CAD 2,600,000 Framing Contract to Construct 150 Homes	19-01-02	CI
Gunpowder Capital Corp. cancelled the acquisition of iBliss Inc. from Easton Pharmaceuticals Inc..	18-11-28	CI
Easton Pharmaceuticals Inc. signed a letter of intent to acquire Boutique Hotel and Real Estate Asset in the Heart of Toronto, Ontario, Canada.	18-09-26	CI
Easton Mulls Acquisitions Of Operating Casino and Hotel Resort in Greece	18-08-22	CI
Easton Pharmaceuticals Acquires Interest in Development Project with in Excess of CAD 30 Million in Profit	18-08-20	CI
Easton Pharmaceuticals Inc. Appoints Panagis Alivizatos to its Board of Directors	18-06-25	CI
Easton Pharmaceuticals Announces Executive Changes	18-06-20	CI
Gunpowder Capital Corp. signed a letter of intent to acquire iBliss Inc. from Easton Pharmaceuticals Inc. for CAD 0.65 million.	18-06-03	CI
Easton Pharmaceuticals Announces Sub-Distribution Agreement with BAYER and BAYER Consumer Care of Switzerland	18-04-16	CI
Easton Pharmaceuticals Announces Appointment of Dr. Daniel Bagi, MD as Director, President of Business Development	18-02-20	CI
Easton Pharmaceuticals, Inc. and BMV Medica S.A. de C.V. Announce Signing of a Closed Sub-Distribution Agreement	18-01-25	CI
Easton Pharmaceuticals, Inc. and BMV Medica S.A. de C.V. Signs Closed Sub-Distribution Agreement with the Legal Entity of BAYER's Consumer Health Division	18-01-25	CI
Easton Pharmaceuticals Inc Appoints Luigi Gentile as Director	18-01-10	CI
Easton Pharmaceuticals & Partner BMV Medica Announce Delivery and Launch of AmnioSense (AL-Sense) in Mexico	17-12-06	CI
Easton Pharmaceuticals Inc. Enters into Sub-Distribution Agreement with Gedeon Richter Plc and Gedeon Richter S.A.P.I de C.V. for AmnioSense	17-08-11	CI

Chart Parallel Industries Inc.

Duration

Period

More charts

Company Profile

Easton Pharmaceuticals, Inc. is a development-stage company engaged in various pharmaceutical sectors and others industries. The Company has a transdermal delivery technology (Viorra Delivery Matrix or VDM), which is incorporated in a line of therapeutic over-the-counter (OTC) products. The Company owns topically-delivered drugs and therapeutic/cosmetic healthcare products focused on cancer and other health problems geared towards female sexual dysfunction, wound healing, pain, motion sickness and other conditions. The Company's products are in various stages of commercialization. The Company's products include Nauseasol, which is a motion sickness gel; Skin Renou HA, which is an anti-aging wrinkle cream; Kenestrin Gel, which is a is a pain relief gel; Viorra, which serves as an aid to the relief of female sexual arousal disorder (FSAD); XILIVE, which is an early-stage cancer drug, and FSAD) drug, which includes a water-based complex polymer matrix.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PARALLEL INDUSTRIES INC.	0.00%	1.34K
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	103B
REGENERON PHARMACEUTICALS, INC.	+1.62%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-16.67%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-38.74%	16.73B
BEIGENE, LTD.	-13.21%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs